Strategic Acquisition
Viyash Scientific’s Subsidiary Signs Agreement to Acquire BioForLife Italia for EUR 16.975 Million
NSE
VIYASH
BSE
512529
Viyash Scientific Limited, through its wholly owned Irish subsidiary Alivira Animal Health Limited, has entered into a binding agreement to acquire 100% shareholding in BioForLife Italia S.r.l., Italy. The acquisition, valued at EUR 16.975 million, is aimed at strengthening the company’s presence in the companion animal healthcare market in Italy through an established distribution platform, customer network, and product portfolio.
PRICE-SENSITIVE TRIGGER
Event: Acquisition of BioForLife Italia S.r.l., Italy
Type: Strategic Acquisition
Impact: Positive
Immediate Effect: The transaction expands Viyash Scientific’s companion animal healthcare business in Europe and strengthens its commercial presence in the Italian veterinary products market.
Key Metrics:
- Acquisition Value: EUR 16.975 million
- Upfront Consideration: EUR 15.0 million payable at closing
- Deferred Consideration: EUR 1.975 million subject to transaction terms
- Stake Acquired: 100%
- Target FY2025 Sales: Approximately EUR 9.0 million
- FY2024 Sales: EUR 8.3 million
- FY2023 Sales: EUR 7.1 million
Highlight:
- Acquisition Value: EUR 16.975 million for complete ownership of BioForLife Italia S.r.l.
What Happened ?
Alivira Animal Health Limited, Ireland, a step-down wholly owned subsidiary of Viyash Scientific Limited, has signed a binding agreement to acquire 100% of BioForLife Italia S.r.l., Milan, Italy.
The transaction is subject to customary closing conditions and applicable regulatory approvals. The acquisition is expected to strengthen the group’s position in the companion animal healthcare segment in Italy by adding an established front-end commercial platform and customer reach.
Key Details
Acquisition Overview:
- Target company: BioForLife Italia S.r.l., Milan, Italy.
- Business focus: Marketing and distribution of veterinary medicines, nutraceuticals, and testing kits for companion animals.
- Geography: Primarily focused on the Italian market.
- Shareholding acquired: 100%.
- Consideration structure: Entirely cash-based.
- Acquiring entity: Alivira Animal Health Limited, Ireland.
Note:
- BioForLife Italia has reported steady revenue growth, with annual sales increasing from EUR 7.1 million in CY2023 to EUR 9.0 million in CY2025, indicating an expanding market presence in Italy’s companion animal healthcare segment.
Risk Analysis
Summary:
- The transaction remains subject to regulatory approvals and customary closing conditions. Integration and execution risks are typical for international acquisitions, although the target operates in a business segment aligned with Viyash Scientific’s existing animal health operations.
Key Risks:
- Completion depends on satisfaction of regulatory and closing conditions.
- Approval requirements under Italian Golden Power regulations.
- Integration of acquired operations into the broader Alivira platform.
- Realization of expected commercial synergies may take time.
Worst Case Scenario:
- Failure to obtain required approvals or delays in transaction completion could postpone strategic benefits and limit the anticipated expansion in the Italian companion animal healthcare market.
Risk Level: Low
Company Commentary
- The acquisition is intended to strengthen and scale the company’s presence in Italy.
- BioForLife provides an established front-end platform with customer reach and product capabilities.
- The transaction aligns with Viyash Scientific’s strategy to expand its companion animal healthcare business.
- Management expects the acquisition to enhance commercial capabilities and market penetration in Europe.
Official Exchange Filing: Viyash Scientific Ltd